CytomX Therapeutics (CTMX) Cash from Operations Growth (5y) (2019 - 2026)

CytomX Therapeutics (CTMX) Cash from Operations Growth (5y) (2019 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 CytomX Therapeutics 582.34 Mn 235.63 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 3.12%
Dec 31, 2025 -5.93%
Sep 30, 2025 8.83%
Jun 30, 2025 -16.68%
Mar 31, 2025 15.81%
Dec 31, 2024 7.55%
Sep 30, 2024 2.33%
Jun 30, 2024 16.67%
Mar 31, 2024 7.77%
Dec 31, 2023 5.24%
Sep 30, 2023 -26.87%
Jun 30, 2023 1.10%
Mar 31, 2023 21.43%
Dec 31, 2022 -15.59%
Sep 30, 2022 -42.61%
Jun 30, 2022 -17.06%
Mar 31, 2022 -16.70%
Dec 31, 2021 -78.48%
Sep 30, 2021 -15.93%
Jun 30, 2021 -30.53%